In patients treated with 6 months of #oxaliplatin-based chemotherapy for stage III #colon_cancer, the prognostic impact of early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) before having received 75% of planned doses was studied from the ACCENT/IDEA databases.

In multivariable analyses, ETD was associated with poorer oncologic outcomes. ETD was associated with a decrease in DFS (HR: 1.61, P < 0.001) and OS (HR: 1.73, P < 0.001). However, this was not the case for EOD (HR: 1.07, P = 0.3 and HR: 1.13, P = 0.1). Meanwhile, patients who received < 50% of the planned cycles of oxaliplatin had poorer outcomes. This data favors discontinuing oxaliplatin while continuing fluoropyrimidine in individuals with significant neurotoxicity having received > 50% of the planned 6-month chemotherapy.